<PAPER><mode2 name='PMC4067716' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='iso-abbrev'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='publisher-id'>DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type='ppub'>1664-5464</issn><issn pub-type='epub'>1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4067716</article-id><article-id pub-id-type='doi'>10.1159/000362871</article-id><article-id pub-id-type='publisher-id'>dee-0004-0131</article-id><article-categories><subj-group subj-group-type='heading'><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Sasaki</surname><given-names>Shoichi</given-names></name><xref rid='aff1' ref-type='aff'>a</xref><xref rid='cor1' ref-type='corresp'>*</xref></contrib><contrib contrib-type='author'><name><surname>Horie</surname><given-names>Yoshiharu</given-names></name><xref rid='aff2' ref-type='aff'>b</xref></contrib></contrib-group><aff id='aff1'><sup>a</sup>Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan</aff><aff id='aff2'><sup>b</sup>Division of Biostatistics, Kitasato University Graduate School, Sagamihara, Japan</aff><author-notes><corresp id='cor1'>*Shoichi Sasaki, MD, PhD, Department of Neurology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 (Japan), E-Mail <email>ssasaki@nij.twmu.ac.jp</email></corresp></author-notes><pub-date pub-type='collection'><season>May-Aug</season><year>2014</year></pub-date><pub-date pub-type='epub'><day>21</day><month>5</month><year>2014</year></pub-date><pub-date pub-type='pmc-release'><day>21</day><month>5</month><year>2014</year></pub-date><volume>4</volume><issue>2</issue><fpage>131</fpage><lpage>139</lpage><permissions><copyright-statement>Copyright © 2014 by S. Karger AG, Basel</copyright-statement><copyright-year>2014</copyright-year><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by-nc/3.0/'><license-p>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Aims</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>To elucidate the efficacy of galantamine on cognition and behavioral and psychological symptoms of dementia (BPSD) in outpatients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) who have switched from donepezil to galantamine.</s></p></sec><sec><title>Materials and Methods</title><p><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>We performed an uninterrupted switch from donepezil to galantamine without a washout period or dose titration in 44 ambulatory outpatients with amnestic MCI (n = 12) or mild-to-moderate AD (n = 32).</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Three months after the switch, the efficacy of galantamine was evaluated with the Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory (NPI) and NPI Brief Questionnaire Form (NPI-Q), respectively, using the Wilcoxon signed-rank test.</s></p></sec><sec><title>Results</title><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>NPI scores improved significantly on BPSD, especially on delusions, agitation and aberrant motor activity in AD patients (p = 0.027); improvement was remarkable in patients with moderate AD (MMSE score 10-19; p = 0.007), while insignificant in those with MCI (MMSE score ≥24; p = 0.648).</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The NPI-Q score also improved significantly regarding both the severity of the disease (p = 0.009) and caregiver distress (p = 0.012) in AD patients.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> MMSE scores hardly improved in either MCI (p = 0.394) or AD patients (p = 0.265).</s></p></sec><sec><title>Conclusions</title><p><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>An uninterrupted switch from donepezil to galantamine could be a useful alternative treatment option for AD patients whose BPSD are unresponsive to donepezil, or whose caregivers are not satisfied with donepezil treatment.</s></p><p><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>© 2014 S.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Karger AG, Basel</s></p></sec></abstract><kwd-group><title>Key Words</title><kwd>Alzheimer's disease</kwd><kwd>Behavioral and psychological symptoms of dementia</kwd><kwd>Donepezil</kwd><kwd>Drug switching</kwd><kwd>Galantamine</kwd><kwd>Mild cognitive impairment</kwd></kwd-group><counts><fig-count count='5'></fig-count><table-count count='1'></table-count><ref-count count='34'></ref-count><page-count count='9'></page-count></counts></article-meta></front><body><sec sec-type='intro' id='sec1_1'><title>Introduction</title><p><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In Alzheimer's disease (AD), besides disturbance of cognitive function, behavioral and psychological symptoms of dementia (BPSD) such as delusions, hallucinations, depression/dysphoria, anxiety, agitation/aggression, elation/euphoria, disinhibition, irritability/lability, apathy/indifference, and aberrant motor activity are common, affecting approximately 90% of patients at some stage of the disease [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Patients with mild AD have psychiatric symptoms (delusions, hallucinations) and emotional symptoms (agitation, dysphoria, anxiety, irritability) as frequently as those with moderate or severe AD [<xref rid='B3' ref-type='bibr'>3</xref>], and BPSD do not necessarily correlate with the severity of cognitive changes [<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B5' ref-type='bibr'>5</xref>].</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, BPSD are a major cause of increased caregiver stress and burden [<xref rid='B6' ref-type='bibr'>6</xref>] and are associated with the decision to institutionalize AD patients [<xref rid='B7' ref-type='bibr'>7</xref>].</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Early and adequate treatment can ameliorate BPSD and improve the quality of life, easing the burden for both the patients with dementia and their caregivers.</s></p><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Galantamine was launched in Japan in March 2011, about 10 years later than donepezil, and is now established as one of the standard therapies for mild to moderate AD.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Galantamine has allosteric modulating activity at the nicotinic acetylcholine receptors (nAChRs) in addition to acting as an acetylcholinesterase inhibitor (AChEI) [<xref rid='B8' ref-type='bibr'>8</xref>], and shows improvement of behavioral and neuropsychiatric symptoms [<xref rid='B9' ref-type='bibr'>9</xref>].</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> In this study, the efficacy of galantamine on the symptoms of cognition and BPSD was evaluated by an uninterrupted switch from donepezil to galantamine with no washout period or dose titration in amnestic mild cognitive impairment (MCI) and AD patients, whose BPSD were unresponsive to donepezil, or whose caregivers were not satisfied with donepezil treatment.</s></p></sec><sec sec-type='materials|methods' id='sec1_2'><title>Materials and Methods</title><sec id='sec2_1'><title>Patients</title><p><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The enrolled subjects were ambulatory outpatients who had MCI or mild to moderate probable AD according to the criteria of the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) [<xref rid='B10' ref-type='bibr'>10</xref>,<xref rid='B11' ref-type='bibr'>11</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The age range of the patients was 62-95 years (n = 46, mean 83.3 years) and 58.7% (n = 27) of the patients were female.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Patients had been taking donepezil for ≥33 months (994 ± 711.7 days) on average and had a Mini-Mental State Examination (MMSE) score of &gt;10.</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> They showed firm radiological evidence of AD on MRI with a prominent atrophy of the hippocampi and a corresponding enlargement of the inferior horns of the lateral ventricles; on SPECT, they showed a reduction of blood flow in the parietal and temporal regions.</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Under the category of amnestic MCI patients, we included those who had an MMSE score of ≥24 and a reduction of blood flow in the precuneus and posterior cingulate gyrus by SPECT (3D-SSP or eZIS) or PET, accompanied by hippocampal atrophy.</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Exclusion criteria for the present study were as follows: evidence of neurodegenerative diseases other than AD that may cause or contribute to dementia such as frontotemporal dementia and dementia with Lewy bodies; cognitive impairment resulting from cerebrovascular dementia; metabolic disturbance such as hepatic, renal, pulmonary and endocrine disturbances; vitamin deficiency; epilepsy, and psychiatric disease.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Patients were eligible only if they had a history of cognitive decline that was gradual in onset and progressive over a period of &gt;7 months, and were living with responsible caregivers.</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Written informed consent to the clinical investigation was obtained from the patients or their caregivers.</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Ultimately, a sample of 46 Japanese outpatients meeting NINCDS-ADRDA criteria for MCI and probable AD were selected as pertinent subjects in the routine clinical setting.</s></p><p><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Safety assessments throughout the study were comprised of physical examinations, vital signs, standard laboratory tests as needed, and monitoring for adverse gastrointestinal symptoms such as nausea, vomiting and diarrhea.</s></p></sec><sec id='sec2_2'><title>Design</title><p><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>An uninterrupted switch from donepezil to galantamine with no washout period or dose titration was performed in MCI and AD patients who had gained little or no benefit from donepezil, or whose caregivers were not satisfied with donepezil treatment.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Treatment with donepezil 5 mg/day, 8 mg/day, or 10 mg/day was switched to the equivalent galantamine dosages of 16 mg/day, 20 mg/day, or 24 mg/day, respectively.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Concurrent use of other AChEIs and additional anti-dementia drugs was not permitted.</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Changes of antidepressants or psychotropic medications such as anxiolytics, hypnotics, and neuroleptics within 6 months before the switch, and addition of such drugs were not permitted.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> MMSE scores and the Japanese version of the Neuropsychiatric Inventory (NPI) including the Caregiver Distress Scale and the Neuropsychiatric Inventory Brief Questionnaire Form (NPI-Q) [<xref rid='B12' ref-type='bibr'>12</xref>] were evaluated at the time just before and 3 months after the switch from donepezil to galantamine.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The NPI is an instrument to assess the frequency and severity of symptoms, and the caregiver distress in 10 behavioral domains (delusions, hallucinations, depression/dysphoria, anxiety, agitation/aggression, elation/euphoria, disinhibition, irritability/lability, apathy/indifference, and aberrant motor activity) of BPSD occurring in patients with dementia [<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The NPI is given as an interview questionnaire, and neuropsychiatric manifestations within each domain are rated by the caregiver in terms of both frequency (1-4) and severity (1-3), yielding a composite symptom domain score (frequency × severity).</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Caregiver distress is rated for each positive neuropsychiatric symptom domain by scores from 0 (no distress) to 5 (extreme distress).</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The NPI has demonstrated stage-specific trends in neuropsychiatric symptoms in AD patients [<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The NPI-Q provides a brief, reliable, informant-based assessment of neuropsychiatric symptoms and associated caregiver distress that may be suitable for use in routine clinical practice [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> It is given as a self-administered questionnaire, as opposed to an interview.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Written instructions for completing the questionnaire form are included for symptom severity and caregiver distress ratings.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The NPI-Q scores in 10 behavioral domains are each rated in terms of the severity of the disease as 0 (absent); 1 (mild); 2 (moderate), and 3 (severe).</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The total NPI-Q severity score represents the sum of individual symptom scores and ranges from 0 to 30.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The NPI-Q caregiver distress scores are rated from 0 (no distress) to 5 (very severe).</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The total NPI-Q distress score represents the sum of individual symptom scores and ranges from 0 to 50.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The Japanese version of the NPI and NPI-Q is sufficiently valid and as reliable as the original version [<xref rid='B12' ref-type='bibr'>12</xref>].</s></p></sec><sec id='sec2_3'><title>Statistical Analysis</title><p><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>MMSE, NPI and NPI-Q scores just before the switch from donepezil to galantamine and 3 months later were compared using the Wilcoxon signed-rank test.</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The level of significance for all comparisons (type I error) was set at p &lt; 0.05.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Moreover, NPI and NPI-Q scores were evaluated in subgroups of patients categorized according to AD severity: MCI (MMSE score ≥24), mild AD (MMSE score 20-23) and moderate AD (MMSE score 10-19) using the Wilcoxon signed-rank test.</s></p></sec></sec><sec sec-type='results' id='sec1_3'><title>Results</title><p><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>A total of 44 out of 46 patients (95.7%) completed the evaluation at 3 months.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Two patients discontinued participation, due in one case to overexcitement and in the other to severe anorexia as a result of dehydration from excessive summer heat, both of which were not associated with side effects.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The clinical and medication profiles of the 44 enrolled patients prior to the switch from donepezil to galantamine are shown in table <xref rid='T1' ref-type='table'>1</xref>.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean age was 83.2 years (n = 44), and 56.8% (n = 25) of the patients were female.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean duration of galantamine treatment was 95.3 days.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Among the 44 patients, 32 patients took galantamine doses of 16 mg/day, 7 patients 20 mg/day, and 5 patients 24 mg/day.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> As for 5 patients to whom memantine had been administered in addition to donepezil for more than 6 months before the switch, the same dose of memantine was maintained after the switch to galantamine.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Other concomitant classes of medication were antihypertensive agents (16 patients, 36.4%), antithrombotic agents (10 patients, 22.7%), hypolipidemic agents (8 patients, 18.2%), antidiabetics (6 patients, 13.6%), memantine (5 patients, 11.4%), an anticoagulant (1 patient, 2.3%) and quetiapine (1 patient, 2.3%).</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The uninterrupted switch from donepezil to galantamine was well tolerated in all patients and was not associated with cholinergic side effects.</s></p><p><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>In the AD group (n = 32, MMSE score 10-23), the mean MMSE score showed no significant benefit from the switch (17.1 ± 3.42 to 17.6 ± 3.57, p = 0.265), while the mean NPI score exhibited statistically significant improvement at 3 months after the switch (18.1 ± 13.77 to 14.7 ± 11.0, p = 0.027) compared with that just before the switch (fig. <xref rid='F1' ref-type='fig'>1</xref>).</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the MCI group (n = 12, MMSE score ≥24), there was no significant beneficial effect either on MMSE (27.4 ± 2.02 to 27.1 ± 2.93, p = 0.394) or NPI (11.2 ± 12.1 to 10.8 ± 12.81, p = 0.648) scores.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Moreover, when separating patients into two groups, i.e., the mild group with MCI + mild AD (n = 20, MMSE score ≥20) and the moderate group with moderately advanced AD (n = 24, MMSE score 10-19), the significant beneficial effect of galantamine on the NPI score in the moderate group (MMSE score 10-19) 3 months after the switch (16.3 ± 16.93 to 13.1 ± 13.31, p = 0.007) contrasted remarkably with the insignificant benefit in the mild group (MMSE score ≥20; 16.1 ± 16.93 to 14.3 ± 14.31, p = 0.39) (fig. <xref rid='F2' ref-type='fig'>2</xref>).</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Among the NPI subdomains, delusions (p = 0.018), agitation (p = 0.034) and aberrant motor activity (p = 0.045) were significantly improved in AD patients (fig. <xref rid='F3' ref-type='fig'>3</xref>).</s></p><p><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The average NPI-Q score was significantly improved in terms of both the severity of the disease (6.2 ± 4.83 to 4.9 ± 3.78, p = 0.009) (fig. <xref rid='F4' ref-type='fig'>4</xref>) and the caregiver distress (6.7 ± 5.74 to 5.3 ± 4.42, p = 0.012) (fig. <xref rid='F5' ref-type='fig'>5</xref>) in AD patients, whereas in MCI patients there was no significant efficacy in disease severity (4.2 ± 3.59 to 4.3 ± 4.01, p = 0.674) or distress burden (4.3 ± 4.35 to 4.8 ± 5.22, p = 0.317).</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The significant beneficial effect of galantamine on the NPI-Q score for disease severity (5.7 ± 3.85 to 4.4 ± 3.44, p = 0.001) and distress burden (6.0 ± 4.77 to 4.6 ± 3.88, p = 0.004) in the moderate group (MMSE score 10-19) contrasted remarkably with the insignificant benefit regarding severity (mean of difference 5.6 ± 5.42 to 5.15 ± 4.26, p = 0.562) and distress burden (6.0 ± 6.34 to 5.8 ± 5.35, p = 0.795) in the mild group (MMSE score ≥20).</s></p></sec><sec sec-type='discussion' id='sec1_4'><title>Discussion</title><p><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>BPSD or non-cognitive symptoms are very common in AD patients [<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B15' ref-type='bibr'>15</xref>] and can be assessed by standardized instruments such as NPI [<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In patients with AD, cognitive impairment and BPSD are correlated [<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, BPSD give rise to noticeable disability in AD patients, an increase in caregiver distress [<xref rid='B16' ref-type='bibr'>16</xref>], and poorer patient quality of life [<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Worsening BPSD represent the main cause of earlier patient institutionalization (earlier nursing home entry) [<xref rid='B7' ref-type='bibr'>7</xref>].</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Therefore, early detection of BPSD and efficient treatment with medication is very important in delaying nursing home placement and improving both patients' and caregivers' quality of life.</s></p><p><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Cholinergic deficiency has been associated with neuropsychiatric symptoms of AD as well as cognitive disturbance [<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B18' ref-type='bibr'>18</xref>]; hence, it is logical to use AChEIs in the treatment of BPSD.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> According to an analysis of four trials on galantamine and behavior in AD, 5-6 months of galantamine treatment reduced behavioral symptoms of AD and the associated caregiver burden; the beneficial effects on the NPI were reported for galantamine versus a placebo [<xref rid='B9' ref-type='bibr'>9</xref>,<xref rid='B19' ref-type='bibr'>19</xref>,<xref rid='B20' ref-type='bibr'>20</xref>,<xref rid='B21' ref-type='bibr'>21</xref>].</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, several clinical trials involving galantamine in patients with mild to moderate AD showed improvement of neuropsychiatric symptoms and the associated caregiver distress [<xref rid='B19' ref-type='bibr'>19</xref>,<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B23' ref-type='bibr'>23</xref>].</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Post hoc analysis of pooled data from three large trials of 3-, 5-, and 6-month galantamine treatment for problematic behavior in AD patients showed a slightly significant benefit of galantamine over the placebo on total NPI scores, and in the domains of agitation/aggression, anxiety, disinhibition, and aberrant motor behavior [<xref rid='B24' ref-type='bibr'>24</xref>].</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In contrast, in another study, the beneficial effect of galantamine on the NPI scores after 3 months of treatment was not statistically significant, likely owing to the short duration of the trial and the exclusion of patients with behavioral problems at baseline [<xref rid='B9' ref-type='bibr'>9</xref>,<xref rid='B25' ref-type='bibr'>25</xref>].</s></p><p><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>The present study showed that AD patients who switched from donepezil to the equivalent dosage of galantamine maintained the same cognitive function on MMSE 3 months after the switch, and the NPI scores in AD patients, in particular the scores in moderately advanced AD patients (MMSE score 10-19), improved significantly, while those in MCI + mild AD patients (MMSE score ≥20) did not, which is consistent with that of a previous report [<xref rid='B9' ref-type='bibr'>9</xref>]; among the subdomains, delusions, agitation and aberrant motor activity were significantly improved.</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Moreover, the significant beneficial effect of galantamine on the NPI-Q score, which is evaluated by a questionnaire through the caregiver, indicates that the caregivers of patients with AD experienced a significant benefit after the switch from donepezil while those of patients with MCI did not.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Thus, the 3 months' duration of galantamine treatment after an uninterrupted switch from donepezil seems to be a long enough period to demonstrate the therapeutic beneficial effect on the NPI and NPI-Q.</s></p><p><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Expression levels of nAChRs are reduced in the brains of AD patients, as compared with age-matched controls [<xref rid='B26' ref-type='bibr'>26</xref>]. nAChRs are located on presynaptic membranes regulating the release of ACh and other neurotransmitters, including glutamate, GABA, 5-HT, and dopamine, via Ca<sup>2+</sup> influx [<xref rid='B27' ref-type='bibr'>27</xref>].</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Anticholinesterase therapy for AD has in common the ability to inhibit cholinesterases [<xref rid='B28' ref-type='bibr'>28</xref>].</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Inhibition of cholinesterases increases the synaptic concentration of ACh, thereby enhancing and prolonging the action of ACh on nicotinic receptors and on muscarinic receptors, leading to improvement of cognitive function.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Galantamine binds to most nAChRs, and induces the release of neurotransmitters such as ACh, dopamine, noradrenaline, 5-HT, and GABA by nicotinic allosteric potentiating ligand action [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Thus, galantamine potentiates the action of ACh on nAChRs and does not alter the activity of nAChRs in the absence of ACh; hence, nicotinic allosteric potentiating ligand action may contribute to the therapeutic effectiveness of galantamine in AD [<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Improvement of the NPI and NPI-Q scores in this study may be due to a nicotinic allosteric potentiating ligand action on AChRs.</s></p><p><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Regarding the washout period for the switch from donepezil to galantamine, there have been a variety of reports [<xref rid='B30' ref-type='bibr'>30</xref>,<xref rid='B31' ref-type='bibr'>31</xref>,<xref rid='B32' ref-type='bibr'>32</xref>].</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, there is no evidence of a loss of symptomatic benefit or changes in cognitive performance with either a 4- or 7-day washout period, and there are fewer gastrointestinal adverse events if the washout period is 4 days rather than 7 days [<xref rid='B30' ref-type='bibr'>30</xref>].</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A switch without a washout period and subsequent dose escalation (8-24 mg/day) over 3 weeks results in an increase in gastrointestinal adverse events, while either fast (weekly increments of 8 mg/day) or slow (monthly increments of 8 mg/day) galantamine dose titration after a 7-day donepezil washout period is well tolerated [<xref rid='B31' ref-type='bibr'>31</xref>].</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In contrast, AD patients switching from donepezil to galantamine without a washout period were reported to tolerate the switch well, with stabilization or improvement in cognitive function, behavior, and activities of daily living in the subsequent 3 months [<xref rid='B32' ref-type='bibr'>32</xref>], although the number of patients examined was very few (n = 4).</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The peak levels of AChE inhibition achieved by the combined effect of donepezil and galantamine were above the level of inhibition achieved by donepezil alone for less than 1 h, suggesting that the same dose escalation profile (starting from 4 mg b.i.d.) that is used for first-time galantamine recipients could be used for patients who previously took donepezil [<xref rid='B33' ref-type='bibr'>33</xref>].</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Thus, given the tolerability and pharmacokinetic properties of galantamine, there is a pharmacokinetic rationale for switching from donepezil to galantamine without a washout period [<xref rid='B33' ref-type='bibr'>33</xref>].</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In fact, the uninterrupted switch from donepezil to the equivalent dosage of galantamine without dose titration in this study was well tolerated and not associated with cholinergic side effects, although galantamine is commonly associated with adverse events such as nausea (17.3%), dizziness (12%), and vomiting (10.7%) [<xref rid='B34' ref-type='bibr'>34</xref>].</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> The therapeutic strategy of no washout period and no dose titration may also be desirable because it provides treatment continuity for patients and continuous cholinergic stimulation.</s></p><p><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>These findings suggest that an uninterrupted switch from donepezil to the equivalent dosage of galantamine with no washout period or dose titration could be a useful alternative treatment option in moderate AD patients, whose BPSD are unresponsive to donepezil, or whose caregivers are not satisfied with donepezil treatment.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> This preliminary study indicates that a larger clinical trial is warranted to determine the efficacy of galantamine for BPSD.</s></p></sec><sec id='sec1_5'><title>Disclosure Statement</title><p>The authors report no conflicts of interest.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank the patients and their caregivers who took part in the study and Dr. S. Shimizu (Medical Research Institute, Tokyo Women's Medical University, Tokyo) for statistical analysis.</p></ack><ref-list><title>References</title><ref id='B1'><label>1</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rovner</surname><given-names>BW</given-names></name><name><surname>Kafonek</surname><given-names>S</given-names></name><name><surname>Filipp</surname><given-names>L</given-names></name><name><surname>Lucas</surname><given-names>MJ</given-names></name><name><surname>Folstein</surname><given-names>MF</given-names></name></person-group><article-title>Prevalence of mental illness in a community nursing home</article-title><source>Am J Psychiatry</source><year>1986</year><volume>143</volume><fpage>1446</fpage><lpage>1449</lpage><pub-id pub-id-type='pmid'>3777239</pub-id></element-citation></ref><ref id='B2'><label>2</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Podgorski</surname><given-names>CA</given-names></name><name><surname>Blazina</surname><given-names>L</given-names></name><name><surname>Leibovici</surname><given-names>A</given-names></name></person-group><article-title>Mental disorders in the nursing home: another perspective</article-title><source>Am J Psychiatry</source><year>1993</year><volume>150</volume><fpage>1063</fpage><lpage>1069</lpage><pub-id pub-id-type='pmid'>8317577</pub-id></element-citation></ref><ref id='B3'><label>3</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Shimabukuro</surname><given-names>J</given-names></name><name><surname>Awata</surname><given-names>S</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name></person-group><article-title>Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients</article-title><source>Psychiatry Clin Neurosci</source><year>2005</year><volume>59</volume><fpage>274</fpage><lpage>279</lpage><pub-id pub-id-type='pmid'>15896220</pub-id></element-citation></ref><ref id='B4'><label>4</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Mega</surname><given-names>MS</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Fiorello</surname><given-names>T</given-names></name><name><surname>Gornbein</surname><given-names>J</given-names></name></person-group><article-title>The spectrum of behavioral changes in Alzheimer's disease</article-title><source>Neurology</source><year>1996</year><volume>46</volume><fpage>130</fpage><lpage>135</lpage><pub-id pub-id-type='pmid'>8559361</pub-id></element-citation></ref><ref id='B5'><label>5</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Mackell</surname><given-names>J</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name></person-group><article-title>Behavioral effects of current Alzheimer's disease treatments: a descriptive review</article-title><source>Alzheimers Dement</source><year>2008</year><volume>4</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type='pmid'>18631950</pub-id></element-citation></ref><ref id='B6'><label>6</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Coen</surname><given-names>RF</given-names></name><name><surname>Swanwick</surname><given-names>GR</given-names></name><name><surname>O'Boyle</surname><given-names>CA</given-names></name><name><surname>Coakley</surname><given-names>D</given-names></name></person-group><article-title>Behaviour disturbance and other predictors of carer burden in Alzheimer's disease</article-title><source>Int J Geriatr Psychiatry</source><year>1997</year><volume>12</volume><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type='pmid'>9152717</pub-id></element-citation></ref><ref id='B7'><label>7</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Steele</surname><given-names>C</given-names></name><name><surname>Rovner</surname><given-names>B</given-names></name><name><surname>Chase</surname><given-names>GA</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name></person-group><article-title>Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease</article-title><source>Am J Psychiatry</source><year>1990</year><volume>147</volume><fpage>1049</fpage><lpage>1051</lpage><pub-id pub-id-type='pmid'>2375439</pub-id></element-citation></ref><ref id='B8'><label>8</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Samochocki</surname><given-names>M</given-names></name><name><surname>Höffle</surname><given-names>A</given-names></name><name><surname>Fehrenbacher</surname><given-names>A</given-names></name><name><surname>Jostock</surname><given-names>R</given-names></name><name><surname>Ludwig</surname><given-names>J</given-names></name><name><surname>Christner</surname><given-names>C</given-names></name><name><surname>Radina</surname><given-names>M</given-names></name><name><surname>Zerlin</surname><given-names>M</given-names></name><name><surname>Ullmer</surname><given-names>C</given-names></name><name><surname>Pereira</surname><given-names>EF</given-names></name><name><surname>Lübbert</surname><given-names>H</given-names></name><name><surname>Albuquerque</surname><given-names>EX</given-names></name><name><surname>Maelicke</surname><given-names>A</given-names></name></person-group><article-title>Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors</article-title><source>J Pharmacol Exp Ther</source><year>2003</year><volume>305</volume><fpage>1024</fpage><lpage>1036</lpage><pub-id pub-id-type='pmid'>12649296</pub-id></element-citation></ref><ref id='B9'><label>9</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kavanagh</surname><given-names>S</given-names></name><name><surname>Gaudig</surname><given-names>M</given-names></name><name><surname>Van Baelen</surname><given-names>B</given-names></name><name><surname>Adami</surname><given-names>M</given-names></name><name><surname>Delgado</surname><given-names>A</given-names></name><name><surname>Guzman</surname><given-names>C</given-names></name><name><surname>Jedenius</surname><given-names>E</given-names></name><name><surname>Schäuble</surname><given-names>B</given-names></name></person-group><article-title>Galantamine and behavior in Alzheimer disease: analysis of four trials</article-title><source>Acta Neurol Scand</source><year>2011</year><volume>124</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type='pmid'>21615354</pub-id></element-citation></ref><ref id='B10'><label>10</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Kawas</surname><given-names>CH</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Koroshetz</surname><given-names>WJ</given-names></name><name><surname>Manly</surname><given-names>JJ</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Mohs</surname><given-names>RC</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Thies</surname><given-names>B</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name></person-group><article-title>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type='pmid'>21514250</pub-id></element-citation></ref><ref id='B11'><label>11</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Gamst</surname><given-names>A</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Snyder</surname><given-names>PJ</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Thies</surname><given-names>B</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name></person-group><article-title>The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type='pmid'>21514249</pub-id></element-citation></ref><ref id='B12'><label>12</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Fukuhara</surname><given-names>R</given-names></name><name><surname>Hyodo</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Toyota</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Shinagawa</surname><given-names>S</given-names></name><name><surname>Hokoishi</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>H</given-names></name><name><surname>Hirono</surname><given-names>N</given-names></name></person-group><article-title>Validity and reliability of the Japanese version of the Neuropsychiatric Inventory Caregiver Distress Scale (NPI D) and the Neuropsychiatric Inventory Brief Questionnaire Form (NPI-Q)</article-title><source>No To Shinkei</source><year>2006</year><volume>58</volume><fpage>785</fpage><lpage>790</lpage><pub-id pub-id-type='pmid'>17052006</pub-id></element-citation></ref><ref id='B13'><label>13</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Rosenberg-Thompson</surname><given-names>S</given-names></name><name><surname>Carusi</surname><given-names>DA</given-names></name><name><surname>Gornbein</surname><given-names>J</given-names></name></person-group><article-title>The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type='pmid'>7991117</pub-id></element-citation></ref><ref id='B14'><label>14</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kaufer</surname><given-names>DI</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Ketched</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>V</given-names></name><name><surname>MacMillan</surname><given-names>A</given-names></name><name><surname>Shelley</surname><given-names>T</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name></person-group><article-title>Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2000</year><volume>12</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type='pmid'>11001602</pub-id></element-citation></ref><ref id='B15'><label>15</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fernández</surname><given-names>M</given-names></name><name><surname>Gobartt</surname><given-names>AL</given-names></name><name><surname>Balañá</surname><given-names>M</given-names></name><collab>COOPERA Study Group</collab></person-group><article-title>Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment</article-title><source>BMC Neurol</source><year>2010</year><volume>10</volume><fpage>87</fpage><pub-id pub-id-type='pmid'>20920205</pub-id></element-citation></ref><ref id='B16'><label>16</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Swearer</surname><given-names>JM</given-names></name><name><surname>Drachman</surname><given-names>DA</given-names></name><name><surname>O'Donnell</surname><given-names>BF</given-names></name><name><surname>Mitchell</surname><given-names>AL</given-names></name></person-group><article-title>Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity</article-title><source>J Am Geriatr Soc</source><year>1988</year><volume>36</volume><fpage>784</fpage><lpage>790</lpage><pub-id pub-id-type='pmid'>3411060</pub-id></element-citation></ref><ref id='B17'><label>17</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>González-Salvador</surname><given-names>T</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Hovanec</surname><given-names>L</given-names></name><name><surname>Roques</surname><given-names>C</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Steele</surname><given-names>C</given-names></name></person-group><article-title>Quality of life in dementia patients in long-term care</article-title><source>Int J Geriatr Psychiatry</source><year>2000</year><volume>15</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type='pmid'>10679850</pub-id></element-citation></ref><ref id='B18'><label>18</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Back</surname><given-names>C</given-names></name></person-group><article-title>The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease</article-title><source>Am J Geriatr Psychiatry</source><year>1998</year><volume>6</volume><issue>2 suppl 1</issue><fpage>S64</fpage><lpage>S78</lpage><pub-id pub-id-type='pmid'>9581223</pub-id></element-citation></ref><ref id='B19'><label>19</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Solomon</surname><given-names>PR</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Kershaw</surname><given-names>P</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>CA</given-names></name></person-group><article-title>5-Month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>2269</fpage><lpage>2276</lpage><pub-id pub-id-type='pmid'>10881251</pub-id></element-citation></ref><ref id='B20'><label>20</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Corey-Bloom</surname><given-names>J</given-names></name><name><surname>Potocnik</surname><given-names>FC</given-names></name><name><surname>Truyen</surname><given-names>L</given-names></name><name><surname>Gold</surname><given-names>M</given-names></name><name><surname>Damaraju</surname><given-names>CR</given-names></name></person-group><article-title>Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2005</year><volume>20</volume><fpage>120</fpage><lpage>132</lpage><pub-id pub-id-type='pmid'>15990426</pub-id></element-citation></ref><ref id='B21'><label>21</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Erkinjuntti</surname><given-names>T</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Damaraju</surname><given-names>CV</given-names></name></person-group><article-title>Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1283</fpage><lpage>1290</lpage><pub-id pub-id-type='pmid'>11965273</pub-id></element-citation></ref><ref id='B22'><label>22</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Raskind</surname><given-names>MA</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Wessel</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><collab>the Galantamine USA-1 Study Group</collab></person-group><article-title>Galantamine in AD: a 6-month, randomized, placebo-controlled trial with a 6-month extension</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>2261</fpage><lpage>2268</lpage><pub-id pub-id-type='pmid'>10881250</pub-id></element-citation></ref><ref id='B23'><label>23</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Gaens</surname><given-names>E</given-names></name><collab>the Galantamine International-1 Study Group</collab></person-group><article-title>Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicentre randomized controlled trial</article-title><source>BMJ</source><year>2000</year><volume>321</volume><fpage>1445</fpage><lpage>1448</lpage><pub-id pub-id-type='pmid'>11110737</pub-id></element-citation></ref><ref id='B24'><label>24</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Rabheru</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Binder</surname><given-names>C</given-names></name></person-group><article-title>Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials</article-title><source>Am J Geriatr Psychiatry</source><year>2005</year><volume>13</volume><fpage>527</fpage><lpage>534</lpage><pub-id pub-id-type='pmid'>15956273</pub-id></element-citation></ref><ref id='B25'><label>25</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rockwood</surname><given-names>K</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><name><surname>Truyen</surname><given-names>L</given-names></name><name><surname>Wessel</surname><given-names>T</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name></person-group><article-title>Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2001</year><volume>71</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type='pmid'>11606667</pub-id></element-citation></ref><ref id='B26'><label>26</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Martin-Ruiz</surname><given-names>CM</given-names></name><name><surname>Court</surname><given-names>JA</given-names></name><name><surname>Molnar</surname><given-names>E</given-names></name></person-group><article-title>α-4 but not α-3 and α-7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease</article-title><source>J Neurochem</source><year>1999</year><volume>73</volume><fpage>1635</fpage><lpage>1640</lpage><pub-id pub-id-type='pmid'>10501210</pub-id></element-citation></ref><ref id='B27'><label>27</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Santos</surname><given-names>MD</given-names></name><name><surname>Alkondon</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>EF</given-names></name><name><surname>Aracava</surname><given-names>Y</given-names></name><name><surname>Eisenberg</surname><given-names>HM</given-names></name><name><surname>Maelicke</surname><given-names>A</given-names></name><name><surname>Albuquerque</surname><given-names>EX</given-names></name></person-group><article-title>The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system</article-title><source>Mol Pharmacol</source><year>2002</year><volume>61</volume><fpage>1222</fpage><lpage>1234</lpage><pub-id pub-id-type='pmid'>11961141</pub-id></element-citation></ref><ref id='B28'><label>28</label><element-citation publication-type='book'><person-group person-group-type='author'><name><surname>Giacobini</surname><given-names>E</given-names></name></person-group><person-group person-group-type='author'><name><surname>Giacobini</surname><given-names>E</given-names></name></person-group><article-title>Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy</article-title><source>Cholinesterases and Cholinesterase Inhibitors</source><year>2000</year><publisher-loc>London</publisher-loc><publisher-name>Martin Dunitz</publisher-name><fpage>181</fpage><lpage>226</lpage></element-citation></ref><ref id='B29'><label>29</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ago</surname><given-names>Y</given-names></name><name><surname>Koda</surname><given-names>K</given-names></name><name><surname>Takuma</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name></person-group><article-title>Pharmacological aspects of the acetylcholinesterase inhibitor galantamine</article-title><source>J Pharmacol Sci</source><year>2011</year><volume>116</volume><fpage>6</fpage><lpage>17</lpage><pub-id pub-id-type='pmid'>21498956</pub-id></element-citation></ref><ref id='B30'><label>30</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wilkinson</surname><given-names>DG</given-names></name><name><surname>Howe</surname><given-names>I</given-names></name><collab>the GAL-GBR-1 Study Group</collab></person-group><article-title>Switching from donepezil to galantamine: a double-blind study of two wash-out periods</article-title><source>Int J Geriatr Psychiatry</source><year>2005</year><volume>20</volume><fpage>489</fpage><lpage>491</lpage><pub-id pub-id-type='pmid'>15852437</pub-id></element-citation></ref><ref id='B31'><label>31</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rasmusen</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Robillard</surname><given-names>A</given-names></name><name><surname>Dunbar</surname><given-names>F</given-names></name></person-group><article-title>Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials</article-title><source>Clin Ther</source><year>2001</year><volume>23</volume><issue>suppl A</issue><fpage>A25</fpage><lpage>A30</lpage><pub-id pub-id-type='pmid'>11396868</pub-id></element-citation></ref><ref id='B32'><label>32</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Edwards</surname><given-names>K</given-names></name><name><surname>Therriault O'Connor</surname><given-names>J</given-names></name><name><surname>Gorman</surname><given-names>C</given-names></name></person-group><article-title>Switching from donepezil or rivastigmine to galantamine in clinical practice</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><fpage>1965</fpage><pub-id pub-id-type='pmid'>15507085</pub-id></element-citation></ref><ref id='B33'><label>33</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Maelicke</surname><given-names>A</given-names></name></person-group><article-title>Pharmacokinetic rationale for switching from donepezil to galantamine</article-title><source>Clin Ther</source><year>2001</year><volume>23</volume><issue>suppl A</issue><fpage>A8</fpage><lpage>A12</lpage><pub-id pub-id-type='pmid'>11396871</pub-id></element-citation></ref><ref id='B34'><label>34</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Richarz</surname><given-names>U</given-names></name><name><surname>Gaudig</surname><given-names>M</given-names></name><name><surname>Rettig</surname><given-names>K</given-names></name><name><surname>Schauble</surname><given-names>B</given-names></name></person-group><article-title>Galantamine treatment in outpatients with mild Alzheimer's disease</article-title><source>Acta Neurol Scand</source><year>2014</year><volume>129</volume><fpage>382</fpage><lpage>392</lpage><pub-id pub-id-type='pmid'>24461047</pub-id></element-citation></ref></ref-list></back><floats-group><fig orientation='portrait' id='F1' position='float'><label>Fig. 1</label><caption><p>Change of NPI score after 3 months in AD patients (mean ± SD; n = 32, p = 0.0027).</p></caption><graphic xlink:href='dee-0004-0131-g01'></graphic></fig><fig orientation='portrait' id='F2' position='float'><label>Fig. 2</label><caption><p>Change of NPI score after 3 months in moderately advanced AD (MMSE score 10-19; mean ± SD; n = 24, p = 0.007).</p></caption><graphic xlink:href='dee-0004-0131-g02'></graphic></fig><fig orientation='portrait' id='F3' position='float'><label>Fig. 3</label><caption><p>Change of NPI score after 3 months in the subdomain of AD patients. Delusion: p = 0.018; agitation: p = 0.034; aberrant motor behavior: p = 0.045.</p></caption><graphic xlink:href='dee-0004-0131-g03'></graphic></fig><fig orientation='portrait' id='F4' position='float'><label>Fig. 4</label><caption><p>Change of NPI-Q subscore for severity of symptoms after 3 months in AD patients (mean ± SD; n = 32, p = 0.009).</p></caption><graphic xlink:href='dee-0004-0131-g04'></graphic></fig><fig orientation='portrait' id='F5' position='float'><label>Fig. 5</label><caption><p>Change of NPI-Q subscore for caregiver distress after 3 months in AD patients (mean ± SD; n = 32, p = 0.012).</p></caption><graphic xlink:href='dee-0004-0131-g05'></graphic></fig><table-wrap orientation='portrait' id='T1' position='float'><label>Table 1</label><caption><p>The clinical and medication profiles of the enrolled patients</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1'></th><th colspan='1' rowspan='1' align='left'>AD</th><th colspan='1' rowspan='1' align='left'>MCI</th><th colspan='1' rowspan='1' align='left'>AD + MCI</th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of patients</td><td colspan='1' rowspan='1' align='left'>32</td><td colspan='1' rowspan='1' align='left'>12</td><td colspan='1' rowspan='1' align='left'>44</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Sex (m/f)</td><td colspan='1' rowspan='1' align='left'>11/21</td><td colspan='1' rowspan='1' align='left'>8/4</td><td colspan='1' rowspan='1' align='left'>19/25</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mean age, years</td><td colspan='1' rowspan='1' align='left'>84.5</td><td colspan='1' rowspan='1' align='left'>79.8</td><td colspan='1' rowspan='1' align='left'>83.2</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Disease duration, months</td><td colspan='1' rowspan='1' align='left'>50.7</td><td colspan='1' rowspan='1' align='left'>34.5</td><td colspan='1' rowspan='1' align='left'>46.3</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mean dosing period of donepezil, days</td><td colspan='1' rowspan='1' align='left'>1,056</td><td colspan='1' rowspan='1' align='left'>829.9</td><td colspan='1' rowspan='1' align='left'>994.3</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mean dosing period of galantamine, days</td><td colspan='1' rowspan='1' align='left'>94.6</td><td colspan='1' rowspan='1' align='left'>97.4</td><td colspan='1' rowspan='1' align='left'>95.3</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mean administered dose of donepezil, mg/day</td><td colspan='1' rowspan='1' align='left'>5.7</td><td colspan='1' rowspan='1' align='left'>6.2</td><td colspan='1' rowspan='1' align='left'>5.8</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mean administered dose of galantamine, mg/day</td><td colspan='1' rowspan='1' align='left'>17.2</td><td colspan='1' rowspan='1' align='left'>17.3</td><td colspan='1' rowspan='1' align='left'>17.2</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of patients taking memantine</td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>1</td><td colspan='1' rowspan='1' align='left'>5</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mean MMSE score</td><td colspan='1' rowspan='1' align='left'>16.7</td><td colspan='1' rowspan='1' align='left'>27.4</td><td colspan='1' rowspan='1' align='left'>19.9</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mean NPI score</td><td colspan='1' rowspan='1' align='left'>18.1</td><td colspan='1' rowspan='1' align='left'>11.2</td><td colspan='1' rowspan='1' align='left'>16.2</td></tr></tbody></table></table-wrap></floats-group></article></PAPER>